Third-generation cryotherapy for prostate cancer in the UK: a prospective study of the early outcomes in primary and recurrent disease
Third-generation cryotherapy for prostate cancer in the UK: a prospective study of the early outcomes in primary and recurrent disease
复制标题
DOI：
10.1111/j.1464-410x.2006.06073.x
复制
发表时间：
2006-05-01
影响因子：
4.5
通讯作者：
Greene, Damian
中科院分区：
文献类型：
--
作者：
Cresswell, Joanne;Asterling, Susan;Greene, Damian
目的介绍使用第三代冷冻治疗在原发性和复发性前列腺癌在一个英国centre.Patients和方法在14个月期间51例前列腺癌患者进行冷冻治疗的早期结果。冷冻治疗31例，放疗或激素消融后挽救治疗20例。前瞻性收集数据，中位随访时间为9个月。结果79%的患者接受初次治疗，67%的患者接受补救治疗，前列腺特异性抗原（PSA）水平降至< 0.5 ng/mL。Gleason分级和PSA水平越高，预后越差。没有患者发生瘘管，4%发生尿潴留，需要经尿道尿道膀胱切除术，4%有持续性尿失禁。勃起功能障碍的发生率很高（86%）。中位住院时间为2 day.CONCLUSION早期结果表明，冷冻治疗为原发性和复发性前列腺癌，特别是老年人和不太适合的患者提供了一种安全的选择。需要长期数据来评估反应的持久性和对生存的影响。
OBJECTIVE To present the early results of the use of third-generation cryotherapy in primary and recurrent prostate cancer at one UK centre.PATIENTS AND METHODS Over a 14-month period 51 patients underwent cryotherapy for prostate cancer. In 31 patients cryotherapy was used as the primary treatment and in 20 as a salvage treatment after radiotherapy or hormone ablation. Data were collected prospectively and the median follow-up was 9 months.RESULTS The prostate-specific antigen (PSA) level decreased to < 0.5 ng/mL in 79% of patients undergoing primary treatment and in 67% of patients undergoing salvage treatment. A higher Gleason grade and PSA levels were associated with a poorer outcome. No patient developed a fistula, 4% developed urinary retention requiring transurethral prostatectomy and 4% had persistent incontinence. The rates of erectile dysfunction were high (86%). The median inpatient stay was 2 days.CONCLUSION Early results suggest that cryotherapy offers a safe alternative for primary and recurrent prostate cancer, particularly for older and less fit patients. Long-term data are required to assess the durability of response and the effect on survival.